Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn’s disease

P Middel, K Reich, F Polzien, V Blaschke, B Hemmerlein, J Herms, M Korabiowska, H-J Radzun

Abstract

Background—The mechanisms involved in the initiation and maintenance of Crohn’s disease are poorly understood. Previous studies have demonstrated an increased number of infiltrating CD4+ T cells within the inflammatory affected bowel wall in Crohn’s disease. Novel therapy approaches using anti-CD4 antibodies are thought to be effective in Crohn’s disease.

Aims—Interleukin 16 (IL-16) has been characterised as a chemokine with selective chemotraction for CD4+ inflammatory T cells. In this study, cellular expression of IL-16 in Crohn’s disease and ulcerative colitis was investigated.

Methods—Expression of IL-16 was analysed in tissue samples of Crohn’s disease, ulcerative colitis, and normal colonic mucosa. Inflammatory cells were characterised applying reverse transcription-polymerase chain reaction, non-radioactive in situ hybridisation, and immunohistochemistry. Double staining methods were used to characterise cells expressing IL-16. The amount of infiltrating CD4+ cells was determined by immunohistochemistry and correlated with the corresponding IL-16+ cell number by step sections.

Results—An increased number of IL-16+ cells in Crohn’s disease in comparison with ulcerative colitis and control specimens was demonstrated. IL-16 was expressed by CD4 and CD8 positive T cells. In addition, active Crohn’s disease tissue revealed a substantial number of IL-16 positive mast cells. The increased number of CD4+ lymphocytes correlated positively with the increased number of IL-16 positive cells in Crohn’s disease.

Conclusion—Our results demonstrate that increased expression of IL-16 in T cells and mast cells in active Crohn’s disease is associated with increased numbers of CD4+ lymphocytes. Local expression of IL-16 seems to play a significant role in the initiation and persistence of the inflammatory process in Crohn’s disease, presumably by IL-16 mediated recruitment of CD4+ cells, mostly lymphocytes, into the bowel wall.


Keywords: Crohn’s disease; interleukin 16; inflammation; chemotaxis

The immune alterations initiating and maintaining Crohn’s disease (CD) as a chronic inflammatory disorder are still poorly understood. Various hypothesis have been proposed to explain the aetiology and pathogenesis of CD, ranging from exposure to an infective agent to aberrant T cell regulation.1 Chronic inflammatory changes in CD include focal lymphocytic infiltrates within the lamina propria and the submucosa, where granulomas with Langhans’ type multinucleated giant cells can also be observed.1 The focal lymphocytic aggregates frequently demonstrate a perivascular distribution, predominantly around small submucosal vessels. These infiltrates consist mainly of naive CD4+ lymphocytes1 expressing the activation markers CD25 and HLA-DR admixed with scattered freshly migrated monocytes and/or macrophages.1 The increased number of CD4+ lymphocytes in intestinal lesions suggests that T cells are responding to antigenic stimulation and contribute to the local inflammatory process.2–4 This assumption is further supported by studies demonstrating CD4+ T cells as the major cellular source of proinflammatory cytokines such as interferon γ, interleukin (IL)-2, and tumour necrosis factor α in CD, representing a so-called TH-1 immune response.1 In addition, it has been shown that clinical improvement in CD can be achieved by reduction of activated T cells by administration of immunosuppressive agents such as cyclosporin A or systemic anti-CD4 antibody.5

Because of the regulatory role of CD4+ T cells in CD, study of the mechanisms responsible for accumulation of these cells is of primary importance. IL-16, originally described as lymphocyte chemoattractant factor, serves as the natural ligand of the CD4 molecule.6 Thus apart from other cytokines and chemokines, IL-16 can selectively attract CD4+ cells, including T cells, monocytes, dendritic cells, and neutrophilic granulocytes.6–11 In addition to its function as a chemokine, IL-16 stimulates expression of the high affinity IL-2 receptor (IL-2R; CD25) and MHC class II on resting T cells.12 Previous studies have shown that IL-16 is produced by a variety of inflammatory cells, including lymphocytes,13 mast cells,14 and eosinophilic granulocytes,13 and epithelial cells such as keratinocytes16 and airway epithelial cells.17

Abbreviations used in this paper: IL, interleukin; CD, Crohn’s disease; UC, ulcerative colitis; NIGID, non-inflammatory gut disorder; RT-PCR, reverse transcription-polymerase chain reaction; mAb, monoclonal antibody; FITC, fluorescein isothiocyanate.
The biological properties of IL-16 prompted us to hypothesise that IL-16 may be involved in accumulation of CD4+ lymphocytes within the inflammatory affected bowel in CD. The main objective of this study was to characterise and determine the phenotype of inflammatory cells expressing IL-16 at the protein and RNA levels, as evaluated by immunohistochemistry and non-radioactive in situ hybridisation, respectively. Furthermore, the number of cells expressing IL-16 was correlated with the number of CD4+ lymphocytes in CD. Our results provide evidence that increased expression of IL-16 by lymphocytes and mast cells is involved in recruitment of CD4+ lymphocytes in CD.

Methods
Tissue Samples
Surgical specimens derived from involved areas of the large intestine of 10 patients with active CD were studied. CD was active in all patients, as confirmed by clinical features, laboratory parameters, as well as macroscopic and histopathological alterations. All patients underwent surgical intervention because of failure of medical treatment. As controls, surgical specimens from the gut of five patients suffering from therapy resistant ulcerative colitis (UC) (table 1) as well as macroscopic and microscopic uninvolved large bowel tissues from five patients with non-inflammatory gut disorder (NIGD) were used (three colon carcinoma and two diverticular disease). For routine morphological analysis, immunohistochemistry, and non-radioactive in situ hybridisation, appropriate tissue specimens were fixed in formalin and embedded in paraffin. Additional representative samples were snap frozen in liquid nitrogen, stored at −80°C, and used for RNA isolation.

RNA Extraction and Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
RNA was isolated from cryoconserved tissue samples using TriReagent according to the manufacturer’s instructions (Sigma, Deisenhofen, Germany) and finally obtained in 30 µl RNase free water. RNA content was determined spectrophotometrically. RNA (1 µg) was used for reverse transcription after a DNase (FPLC-pure DNaseI, Pharmacia, Freiburg, Germany) digestion step. cDNA synthesis was performed in a total volume of 20 µl RNase free water including 1.5 µM oligo-dT primer, 0.4 mM of each deoxynucleotidetriphosphate (both MBI Fermentas, St Leon-Rot, Germany), and 200 U of reverse transcriptase (SuperScriptII; Gibco, Karlsruhe, Germany).

The oligonucleotide primer sequences were determined manually according to the published sequences in GenBank for β-actin (X00351) and IL-16 (M90391). Polymerase chain reaction (PCR) conditions were as follows: β-actin β-actin-fw-primer: 5'-CTA CAA TGAGCTGGTGTTG-GC-3'; β-actin-rev-primer: 5'-CATCACGAGCTGGTGTTG-GC-3'; product size: 270 bp) three minutes at 95°C, 35 cycles of 40 seconds at 95°C, 45 seconds at 57°C, 1.5 minutes at 72°C, followed by a final extension step of seven minutes at 72°C; IL-16 (IL-16-fw-primer: 5'-ATG CCGGAGCTCAACTGGCTCACT-3'; IL-16-rev-primer: 5'-GCCACCCAGCTGCAAA-3'; product size: 261 bp) three minutes at 95°C, 35 cycles of 40 seconds at 95°C, 40 seconds at 62°C, one minute at 72°C, and final elongation of seven minutes at 72°C. The PCR products were visualised on 1% agarose gels by staining with ethidium bromide. To exclude amplification of genomic sequences, PCR primers were designed to amplify cDNA fragments that span at least one intron of the corresponding gene. cDNA from a human lymph node was used as a positive control template for each primer pair. Negative controls with water instead of cDNA were always included. A PCR reaction was considered to be positive when a single band of correct product length could be detected. Amplification of correct PCR products was controlled by asymmetric restriction enzyme digestion and sequencing with an ABI310 automatic sequencer using the rhodamine-dye-terminator kit according to the manufacturer’s instructions (Perkin Elmer, Darmstadt-Weiterstadt, Germany).

Cloning of PCR Products
For generation of the IL-16 riboprobe for quantitative real time RT-PCR or in situ hybridisation, PCR products were cloned into the blunt end Smal restriction site of the transcription vector BlueScript II KS plasmid. Briefly, blunt end PCR products were generated using Vent polymerase (Pharmacia) according to the PCR cycling conditions, as mentioned above. After micro spin column purification (Pharmacia, Heidelberg, Germany), the blunt end PCR products were ligated into a Smal restricted BlueScript II KS plasmid using T4-DNA-ligase at 16°C overnight and transformed into the CaCl2 competent Escherichia coli strain DH5α. After propagation under standard culture conditions the plasmids were isolated using the alkaline lysis procedure. Cloning of IL-16 specific PCR fragments was confirmed by cycle sequencing with the rhodamine-dye-terminator kit using an ABI 310 sequencer according to the manufacturer’s instructions (Perkin-Elmer). Riboprobes were generated by in vitro transcription using T3 or T7 polymerase (Boehringer, Mannheim, Germany). The amount of cRNA transcripts was monitored by 1% agarose gel electrophoresis and determined spectrophotometrically.

Real Time Quantitative RT-PCR Analysis
Quantification of IL-16 mRNA expression by RT-PCR was performed on an iCycler IQ real time detection system (Bio-Rad, Hercules, California, USA). For RT-PCR, a one step RT-PCR kit (Qiagen, Hilden, Germany) was used. The 15 µl reaction from this kit was supplemented with 150 ng total cellular RNA, 0.6 µM each of the gene specific primers, 4 U

www.gutjnl.com
IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease

IL-16 expression in Crohn's disease
a sealed humidified chamber containing 50% formamide. Non-specific binding or unbound probes were removed by the following post-hybridisation washes: 1×SSC/0.1%SDS at room temperature (2×5 minutes) and 0.2×SSC/0.1%SDS at 60°C (2×10 minutes) followed by RNase digestion (20 µg/ml; Gibco, Karlsruhe, Germany) for 30 minutes at 37°C. Finally, sections were washed in TBS containing 0.1% Tween 20 (Boehringer).

Hybridisation signals were detected using a sheep polyclonal antibody F(ab)2 fragment against digoxigenin conjugated with alkaline phosphatase (1:500; Boehringer). Alkaline phosphatase activity was visualised using 5-bromo-4-chloro-3-indolyl phosphate as substrate and nitroblue tetrazolium as coupler (Boehringer). For each tissue section sense riboprobes served as controls.

In some cases hybridised specimens were incubated with mAbs Ki-M1P recognising monocytes/macrophages, Ki-M4P recognising follicular dendritic cells (kindly provided by Professor MR Parwaresch, Kiel, Germany), CD3 for T cells, CD20 for B cells, NK-1 for natural killer cells, and S100 protein recognising interdigitating dendritic cells (Dako) followed by a rabbit antimouse Ig FITC (Dako) for evaluation by immunofluorescence.

COUNTING AND DATA ANALYSIS
Evaluation of immunoreactivity was performed on step sections stained for IL-16 and CD4 by two blinded evaluators. Corresponding areas of the step sections were marked and high power fields were counted with an eyepiece graticule at 400× magnification. The results were expressed as mean counts from a total of five high power fields per slide. The within observer coefficient of variation for repeated counts was less than 5%.

Data were analysed using a statistical package (Systat version 5.1; Systat Inc, Evanston, USA). Statistical comparisons were performed using ANOVA, and subsequent comparisons were made using the Mann-Whitney U test.
Results

QUANTITATIVE RT-PCR OF IL-16 mRNA IN CD

IL-16 mRNA expression was analysed in tissue samples affected by active CD (n=5), UC (n=5), and from normal controls without signs of inflammation (n=5) by RT-PCR with oligonucleotide primers specific for the human IL-16 cDNA. As an internal control RT-PCR for the housekeeping gene β-actin was performed (data not shown). IL-16 specific products were amplified from mRNA probes isolated from all tissue samples investigated.

For quantification of IL-16 mRNA expression in tissue samples, a method of real time quantitative RT-PCR was established using iCycler technology. IL-16 mRNA levels in equal amounts of total RNA from tissue samples were calculated by reference to a standard curve which was obtained by one step RT-PCR containing different concentrations of in vitro generated IL-16 cRNA (IL16-standards), with a dilution range of 1 to 1000 attomoles (fig 1A, B). Quantification results are given as attomoles per µg total cellular RNA of each investigated tissue sample. In total RNA isolated from tissues with active CD, a significant increase in expression of IL-16 mRNA was determined compared with UC (p<0.005) and NIGD (p<0.001) and expression of IL-16 mRNA in UC was moderately higher than that in NIGD (p=0.054) (fig 1C).

DISTRIBUTION PATTERN OF IL-16 EXPRESSION WITHIN THE BOWEL WALL

In further experiments, RT-PCR findings were confirmed by immunohistochemistry using an IL-16 specific antibody and by non-radioactive in situ hybridisation. Both methods showed comparable results. In NIGD, IL-16 expression was virtually restricted to a few cells of the lamina propria and within the surface epithelium (fig 2A, E). The same pattern of IL-16 expression was observed for specimens affected by UC but showing an increased number of IL-16 positive cells within the lamina propria (fig 2B). In CD, IL-16 was found to be expressed within the inflammatory infiltrate of the entire bowel wall. Within the mucosa, increased numbers of positive cells were found within the lymphocytic infiltrates of the lamina propria (fig 2C, F) and within the epithelium.
representing intraepithelial lymphocytes. Furthermore, numerous IL-16 positive cells were observed adjacent to blood vessels representing freshly migrated cells (fig 2G). The perivascular pattern was predominately found in the deeper layers of the bowel wall comprising the submucosa, muscularis propria, and subserosal tissue. Granulomas in CD did not demonstrate expression of IL-16 in the central epitheloid and giant cells in contrast with the surrounding lymphocytes (fig 2H).

CELLULAR EXPRESSION OF IL-16

To characterise the phenotype of inflammatory cells that express IL-16, double labelling experiments combining immunofluorescence by laser scanning microscopy or non-radioactive in situ hybridisation with immunofluorescence were performed. Most IL-16 positive cells were identified as CD4 (fig 3A) or CD8 (fig 3B) positive T cells. In addition, increased expression of IL-16 by mast cells was found in cases of CD (fig 3C). IL-16 positive mast cells were observed within the lamina propria and in the vicinity of blood vessels within the submucosa or deeper layers of the bowel wall. Furthermore, expression of IL-16 was observed in very few eosinophilic granulocytes. Expression of IL-16 by neutrophilic granulocytes could not be found. Also, expression of IL-16 protein or mRNA could not be found by natural killer cells (detected by the mAb NK-1), macrophages (detected by the mAb Ki-M1P), dendritic cells of either T or B accessory function (detected by the mAbs to S-100 protein and Ki-M4P, respectively), or B lymphocytes (detected by the mAb CD20) (fig 4). By applying non-radioactive in situ hybridisation, we found a few basal epithelial crypt cells displaying IL-16 expression. These cells were found in comparable numbers in CD, UC, and NIGD. Applying immunohistochemistry however, IL-16 expression by these cells could not be confirmed at the protein level.

The increased number of IL-16+ cells within the mucosa of CD in comparison with UC and NIGD proved to be statistically significant (p<0.001) whereas there was no significant difference between the number of IL-16 positive cells in cases of UC and NIGD (p=0.232) (fig 5A). Further investigation of tissue samples from macroscopically unaffected mucosa compared with inflamed colonic mucosa from the same patient revealed a significant increase in IL-16 positive cells (p<0.001) whereas there was no significant difference between the number of IL-16 positive cells in unaffected mucosa of CD versus UC (p=0.1866) and NIGD (p=0.142; data not shown). Furthermore, a significant correlation was found between numbers of CD4+ lymphocytes and numbers of IL-16+ cells (r²=0.77, p<0.001) (fig 5B). As all tissue specimens were exclusively derived from the mucosa of different segments of the large bowel, variations in results caused by differences in the cellular composition of the bowel segment investigated (such as comparing specimens from the small intestine with those derived from the large bowel) were not expected.

Figure 3 Cellular expression of interleukin 16 (IL-16) in Crohn’s disease (CD). Two colour immunofluorescence was used to determine expression of IL-16 (rhodamine-red X, red fluorescence) by double labelling with antibodies for CD4 (A, ×600), CD8 (B, ×600; both green fluorescence), or mast cell specific tryptase (C;×400, green fluorescence). Cells showing coexpression of IL-16 were visualised after digital negative colour subtraction of the single fluorescence images by a yellow colour (open arrows). Most IL-16 positive cells were found to express either CD4 (A) or CD8 (B), representing the CD3+ T cell population. Additionally, IL-16 expression was observed in mast cells (C) whereas numerous mast cells showed no coexpression of IL-16 (closed arrows). Non-specific staining was excluded by negative controls with irrelevant primary antibody (D, ×400).

Figure 4 In situ interleukin 16 (IL-16) mRNA expression in Crohn’s disease (CD). IL-16 mRNA was detected by non-radioactive in situ hybridisation combined with indirect immunofluorescence for the T cell marker CD3 (A, ×200), the monocyte/macrophage marker Ki-M1P (B, ×200), and S-100 protein recognising dendritic cells (C, ×200). Numerous IL-16 mRNA positive cells were found within the lamina propria in CD. The majority of IL-16 mRNA positive cells were found to be T cells showing coexpression for CD3 (A). No expression of IL-16 mRNA was observed by Ki-M1P positive macrophages (B) or S-100 protein positive dendritic cells (C). Negative controls for in situ hybridisation with sense riboprobe (D, upper, ×200) and immunofluorescence with irrelevant primary antibody (D, lower, ×200).
Table 1 Clinical data, including drug treatment and localisation of tissue samples, of cases analysed in the study.

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age (y)</th>
<th>Sex</th>
<th>Duration of disease (y)</th>
<th>Localisation</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD1</td>
<td>27</td>
<td>M</td>
<td>13</td>
<td>Descending colon</td>
<td>Prednisolone</td>
</tr>
<tr>
<td>CD2</td>
<td>35</td>
<td>F</td>
<td>14</td>
<td>Sigmoid colon</td>
<td>Mesalazine</td>
</tr>
<tr>
<td>CD3</td>
<td>59</td>
<td>M</td>
<td>7</td>
<td>Ascending colon</td>
<td>Prednisolone</td>
</tr>
<tr>
<td>CD4</td>
<td>37</td>
<td>F</td>
<td>8</td>
<td>Transverse colon</td>
<td>Prednisolone</td>
</tr>
<tr>
<td>CD5</td>
<td>49</td>
<td>F</td>
<td>5</td>
<td>Ascending colon</td>
<td>Mesalazine</td>
</tr>
<tr>
<td>CD6</td>
<td>46</td>
<td>M</td>
<td>11</td>
<td>Ascending colon</td>
<td>Prednisolone</td>
</tr>
<tr>
<td>CD7</td>
<td>25</td>
<td>M</td>
<td>5</td>
<td>Ascending colon</td>
<td>Budesonide/mesalazine</td>
</tr>
<tr>
<td>CD8</td>
<td>18</td>
<td>M</td>
<td>9</td>
<td>Ascending colon</td>
<td>Budesonide/mesalazine</td>
</tr>
<tr>
<td>CD9</td>
<td>36</td>
<td>M</td>
<td>5</td>
<td>Rectum</td>
<td>Mesalazine</td>
</tr>
<tr>
<td>CD10</td>
<td>34</td>
<td>M</td>
<td>2</td>
<td>Ascending colon</td>
<td>None</td>
</tr>
<tr>
<td>UC1</td>
<td>46</td>
<td>F</td>
<td>22</td>
<td>Transverse colon</td>
<td>5-ASA</td>
</tr>
<tr>
<td>UC2</td>
<td>26</td>
<td>F</td>
<td>9</td>
<td>Sigmoid colon</td>
<td>5-ASA/prednisolone</td>
</tr>
<tr>
<td>UC3</td>
<td>55</td>
<td>M</td>
<td>11</td>
<td>Rectum</td>
<td>5-ASA/prednisolone</td>
</tr>
<tr>
<td>UC4</td>
<td>35</td>
<td>M</td>
<td>11</td>
<td>Sigmoid colon</td>
<td>5-ASA/prednisolone</td>
</tr>
<tr>
<td>UC5</td>
<td>62</td>
<td>M</td>
<td>8</td>
<td>Transverse colon</td>
<td>5-ASA/prednisolone</td>
</tr>
</tbody>
</table>

CD, Crohn’s disease; UC, ulcerative colitis; 5-ASA, 5-aminosalicylic acid.

Figure 5 Quantitative analysis of interleukin 16 (IL-16)+ and CD4+ cell numbers in non-inflammatory gut disorder (NIGD), ulcerative colitis (UC), and Crohn’s disease (CD). (A) Number of IL-16 positive cells within the lamina propria in tissue specimens from patients with NIGD, UC, and CD. Results are expressed as number of positive cells per field. IL-16 protein positive cells were significantly increased in CD compared with NIGD (p<0.001) and UC (p<0.001). No significant difference was observed between UC and NIGD (p=0.232). (B) Significant correlations between IL-16+ cells and CD4+ cell infiltration in NIGD, UC, and CD.

Discussion

The inflammatory infiltrate in active CD is characterised by an increased number of lymphocytes expressing the CD4 antigen. CD4+ T cells belong either to the freshly migrated CD45RA+ subtype, representing naive T cells, or to T cells expressing CD45RO, representing the memory subtype. It is hypothesised that cell renewal by migration of naive T cells into the inflamed bowel wall plays an important part in perpetuation of the inflammatory process in CD. However, the precise mechanisms responsible for recruitment of CD4+ T cells within the inflamed gut in CD are still unclear. To investigate the potential role of IL-16, a novel cytokine serving as a specific chemokine for CD4+ cells, we analysed expression of IL-16 at the protein and RNA levels in CD using immunohistochemistry and non-radioactive in situ hybridisation, respectively. Furthermore, cell types expressing IL-16 in CD were characterised by dual colour immunofluorescence and confocal laser scanning microscopy or non-radioactive in situ hybridisation combined with indirect immunofluorescence.

Our results showed a statistically significant increase in IL-16 mRNA (figs 1, 4) and IL-16 protein positive cells in CD in comparison with UC and NIGD (figs 2, 5). Interestingly, we did not find increased numbers of IL-16 positive cells in uninvolved mucosa of patients suffering from active CD compared with UC or NIGD. Thus increased expression of IL-16 seems to be restricted to sites of inflamed mucosa in CD. Consistent with prior observations, lesion biopsies from patients with acute CD were characterised by an increased number of infiltrating CD4+ T cells within the inflammatory affected bowel wall. In addition, our results provided evidence for a positive correlation between the number of infiltrating CD4+ lymphocytes and the number of IL-16+ cells in CD, UC, and biopsies from NIGD (fig 5). To exclude differences caused by variations in cell numbers within the lamina propria from different anatomical sites, all tissue specimens were obtained from the large bowel of patients suffering from active CD, UC, or NIGD. Furthermore, differences resulting from different therapy modalities such as application of non-steroid therapeutics or administration of local or systemic steroids were not observed when comparing patients suffering from CD or UC (table 1).

By applying double labelling procedures and immunostaining of serial sections, we showed that different inflammatory cell types comprising CD4 and CD8 positive T cells, mast cells, and a few eosinophilic granulocytes were responsible for production of IL-16 in CD as well as in UC, and to a lesser extent in NIGD (fig 3). Expression of IL-16 was not observed at the RNA or protein level in neutrophilic granulocytes, natural killer cells, B lymphocytes, monocytes/macrophages, dendritic cells, or fibroblasts, which in recent studies have been shown to partly produce IL-16.
Originally, IL-16 was found to be expressed by circulating T cells of the CD4+ and CD8+ subsets. CD4+ T cells constitutively synthesize the bioactive form of IL-16, which is released on stimulation by antigen, mitogen, serotonin, and histamine whereas CD4+ T cells were found to contain constitutive IL-16 mRNA as well as the 80 kDa putative precursor molecule but not the preformed 14 kDa bioactive protein. CD4+ T cells release the bioactive IL-16 protein following mitogen, antigen, or anti-CD3 stimulation by a process that requires transcription and translation of new protein. By northern blot analysis, it was shown that IL-16 mRNA expression is constitutively found abundantly in human lymphoid tissue, including lymph node, spleen, and thymus. Interestingly, IL-16 mRNA transcripts were not detected by northern blot analysis of RNA isolated from tissue specimens of the small and large bowel. The latter finding is in contrast with our results obtained by RT-PCR (fig 1), in situ hybridisation, and immunohistochemistry (fig 2A) in biopsy specimens from patients with NIGD. This fact may be explained by the different methods and tissue specimens used for investigation of IL-16 mRNA expression. In the present study, IL-16 mRNA expression was determined by one step RT-PCR which is a much more sensitive method compared with northern blot analysis. Furthermore, the tissue specimens investigated in the present study were derived from the mucosa and submucosa, sites which contain a substantial number of IL-16 positive cells in non-inflammatory conditions, but not from deeper layers such as the muscularis propria and subserosa, which are devoid of IL-16 positive cells in the normal bowel. Thus lack of IL-16 mRNA expression in northern blots may be due to low numbers of IL-16 positive cells restricted to the mucosa in non-inflammatory affected bowel. In addition, our results provide evidence that IL-16 predominantly expressed by CD4+ and CD8+ T cells participates in immune homeostasis in the non-diseased state of the mucosa associated lymphatic tissue of the alimentary tract. Expression of IL-16 in epithelial cells of the mucosa, as recently shown for epithelial cells of the respiratory tract or keratinocytes, was only observed in a few cells of the basal crypts by in situ hybridisation in CD, UC, and NIGD at the same level. This finding was not confirmed for IL-16 protein expression by immunohistochemistry. Epithelial cells of the bowel thus do not seem to contribute to expression of IL-16 in normal or inflammatory affected bowel, which is in contrast with the results observed in atopic asthma and atopic dermatitis.

Mast cells have been shown to express a wide range of chemokines, some of which possess chemotactic activities for T cells such as RANTES, IL-8, MCP-1, MIP-1α, and MIP-1β. Recently, the human leukemic mast cell line HMCL was reported to express IL-16 mRNA. Expression of IL-16 protein was also identified by intracytoplasmic cytokine staining and flow cytometry of cultures from human bone marrow derived mast cells as well as from human mast cell lines. Release of bioactive IL-16 was noted after stimulation. Furthermore, in a more recent study, mast cells were shown to express IL-16 protein in biopsies of acute atopic asthma, where they comprised about 10% of the total cells expressing IL-16 within the inflammatory infiltrate. By digital confocal laser scanning microscopy, as well as by double immunohistochemistry (data not shown), we found expression of IL-16 within the cytoplasm of about 40–50% of the mast cells present in CD (fig 3C).

The present study indicates that increased production of IL-16 may be an important factor for recruitment of CD4+ cells in CD. Determining the distribution and expression of IL-16 in the human alimentary tract seems to be important for the design of drug delivery or targets of novel immune therapy approaches, focusing on specific cells that generate signals responsible for recruitment of CD4+ lymphocytes at sites of inflammation in inflammatory bowel diseases such as CD. For an understanding of the efficacy and immune modulating effects of new therapies, further investigations of the basic mechanisms underlying activation of the CD4 antigen by its natural ligand IL-16 are required. Prior investigations as well as our results provide evidence that production and release of IL-16 results in migration, activation, and maturation of CD4+ T lymphocytes in CD, thus initiating and maintaining the chronic inflammatory process.
We thank Mr K Müller for excellent art work and Mrs K Koch for critically reading the manuscript.


Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn's disease

P Middel, K Reich, F Polzien, V Blaschke, B Hemmerlein, J Herms, M Korabiowska and H-J Radzun

Gut 2001 49: 795-803
do: 10.1136/gut.49.6.795

Updated information and services can be found at:
http://gut.bmj.com/content/49/6/795

These include:

References
This article cites 26 articles, 9 of which you can access for free at:
http://gut.bmj.com/content/49/6/795#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Crohn's disease (932)
Ulcerative colitis (1113)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/